Trial · NCT05239221
Registered outcomes15
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 15 of 15
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Treatment Emergent Adverse Events (TEAEs) | Up to 2 weeks in Part A and Part B, and up to 3 months in Part C | Number of Treatment Emergent Adverse Events (TEAEs), as assessed by medDRA (v25). |
| Secondary | Observed Maximum Concentration (Cmax) - Part A | 24 hours | Observed maximum concentration (Cmax) of AZP-3601 (pg/mL) in Part A |
| Secondary | Observed Maximum Concentration (Cmax) - Part B | Day 1, Day 14 | Observed maximum concentration (Cmax) of AZP-3601 (pg/mL) in Part B |
| Secondary | Observed Maximum Concentration (Cmax) - Part C | Day 1, Day 14, Day 28, Day 84 | Observed maximum concentration (Cmax) of AZP-3601 (pg/mL) in Part C. |
| Secondary | Area Under the Plasma-drug Concentration Time Curve (AUC) - Part A | 24 hours | Area under the plasma-drug concentration time curve (AUC) (pg\*h/mL) in Part A |
| Secondary | Area Under the Plasma-drug Concentration Time Curve (AUC) - Part B | Day 1, Day 14 | Area Under the Plasma-drug Concentration Time Curve (AUC) (pg\*h/mL) in Part B |
| Secondary | Area Under the Plasma-drug Concentration Time Curve (AUC) - Part C | Day 1, Day 14, Day 28, Day 84 | Area Under the Plasma-drug Concentration Time Curve (AUC) (pg\*h/mL) in Part C. |
| Secondary | Calcium Corrected for Albumin - Part A | 24 hours | Levels of calcium corrected for albumin (mg/dL) in Part A |
| Secondary | Calcium Corrected for Albumin - Part B | 24 hours, Day 14 | Levels of calcium corrected for albumin (mg/dL) in Part B |
| Secondary | Calcium Corrected for Albumin - Part C | Day 1, Day 14, Day 28 and Day 84 | Levels of calcium corrected for albumin (mg/dL) in Part C. |
| Secondary | Serum Phosphate - Part A | 24 hours | Serum phosphate levels (mg/dL) in Part A |
| Secondary | Serum Phosphate - Part B | Day 1, Day 14 | Serum phosphate levels (mg/dL) in Part B |
| Secondary | Serum Phosphate - Part C | Day 1 (H0), Day 14 (H2), Day 28 (H2) and Day 84 (H2) | Serum phosphate levels (mg/dL) in Part C. |
| Secondary | Daily Dose of Oral Calcium and Active Vitamin D - Part C | Day 28 and Day 43 | Daily dose of oral calcium and active vitamin D for patients treated in Part C. |
| Other | Calcium Excretion Rate 24h- Part C | Day 1, Day 14, Day 28 and Day 84 | 24 hour calcium excretion rate (mg/24h) in Part C. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05239221/registered